Bridging the gap: Addressing CV risk in adults with T2D and CKD with Dr Yassir Javaid, Dr Toomas Sarev & Dr Brian Camilleri

Meeting Objectives:
• Understand how T2D and/or CKD can increase CV risk, impacting morbidity and mortality
• Review the burden and interconnectivity of T2D, CKD and CVD and highlight the gap in SGLT2i uptake
• Explore the key treatment guidelines regarding early prescribing of SGLT2i’s for optimal patient outcomes
• Reflect on key trial data that supports the role of empaglifloxin in addressing CV risk and other key benefits
• Understand the prescribing considerations and practicalities for empagliflozin

To book a space on this remote session please email James Stickland  – stickland_james@lilly.com